4.0
Oct 4, 2017
Current employee
São Paulo, São Paulo
Recommend
CEO approval
Business Outlook
Pros
Excellent portfolio, lean structure, science driven, provide drug access to patientrs regardless of theor income and geographic location. Strong in Infectious Diseases, expanshion to inflammation and Oncology
Cons
Work life balance needs improvement, result of a lean structure. Carreer development is a topic to be addressed. Decrease in stock price after successful launch of Sovaldi